Hylapharm LLC
- UEI
- D78KUMZNMEL5
- CAGE
- 66QK4
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Website
- hylapharm.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Targeted nanoparticle treatment for breast cancer stem cells | National Cancer Institute (NIH) | $299,813 |
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Aerosolized platinum nanoparticle chemotherapy for lung cancer | National Cancer Institute (NIH) | $298,065 |
Quick answers
Is Hylapharm LLC registered in SAM.gov?
Hylapharm LLC's SAM.gov registration expired on November 5, 2023.
What is Hylapharm LLC's most recent federal award?
Hylapharm LLC's most recent federal grant award is Aerosolized platinum nanoparticle chemotherapy for lung cancer (R43CA203142), from National Cancer Institute (NIH), on February 1, 2017.
On GovTribe
See Hylapharm LLC's full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors